Genomic analysis of lung-tumour evolution has been used to create personalized blood tests that enable successful clinical monitoring for early signs of cancer relapse — a promising step on the road to precision medicine. See Article p.446
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
Journal of Experimental & Clinical Cancer Research Open Access 13 September 2017
-
Circulating tumor DNA for personalized lung cancer monitoring
BMC Medicine Open Access 17 August 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
20 July 2017
An earlier version of this article spelled the ERBB2 gene name incorrectly.
Notes
References
Abbosh, C. et al. Nature 545, 446–451 (2017).
Jamal-Hanjani, M. et al. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1616288 (2017).
Diaz, L. A. & Bardelli, A. J. Clin. Oncol. 32, 579–586 (2014).
Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Nature Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2017.14 (2017).
Wan, J. C. M. et al. Nature Rev. Cancer 17, 223–238 (2017).
Beaver, J. A. et al. Clin. Cancer Res. 19, 2643–2650 (2014).
Garcia-Murillas, I. et al. Sci. Transl. Med. 7, 302ra133 (2015).
Tie, J. et al. Sci. Transl. Med. 8, 346ra392 (2016).
Author information
Authors and Affiliations
Corresponding author
Related links
Rights and permissions
About this article
Cite this article
Bardelli, A. Personalized test tracks cancer relapse. Nature 545, 417–418 (2017). https://doi.org/10.1038/545417a
Published:
Issue Date:
DOI: https://doi.org/10.1038/545417a
This article is cited by
-
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
Journal of Diabetes & Metabolic Disorders (2018)
-
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
Journal of Experimental & Clinical Cancer Research (2017)
-
Circulating tumor DNA for personalized lung cancer monitoring
BMC Medicine (2017)
-
Correction
Nature (2017)